Cargando…

Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study

INTRODUCTION: Fatty acid content in plasma and red blood cells (RBCs) may provide insight into potential physiologic benefits of omega-3 fatty acids. Icosapent ethyl is a pure prescription form of eicosapentaenoic acid (EPA) ethyl ester approved by the US Food and Drug Administration at a dose of 4 ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ballantyne, Christie M., Manku, Mehar S., Bays, Harold E., Philip, Sephy, Granowitz, Craig, Doyle, Ralph T., Juliano, Rebecca A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525216/ https://www.ncbi.nlm.nih.gov/pubmed/30788718 http://dx.doi.org/10.1007/s40119-019-0131-8

Ejemplares similares

Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis
por: Brinton, Eliot A., et al.
Publicado: (2018)

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
por: Brinton, Eliot A, et al.
Publicado: (2013)

Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies
por: Bays, Harold E., et al.
Publicado: (2013)

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses
por: Peterson, Benjamin E., et al.
Publicado: (2020)

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
por: Majithia, Arjun, et al.
Publicado: (2021)

Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT
por: Olshansky, Brian, et al.
Publicado: (2023)

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI
por: Peterson, Benjamin E., et al.
Publicado: (2022)

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
por: Bhatt, Deepak L., et al.
Publicado: (2017)

Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment
por: Weintraub, William S., et al.
Publicado: (2022)

Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200–499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients
por: Toth, Peter P, et al.
Publicado: (2019)

Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)
por: Ambrosy, Andrew P., et al.
Publicado: (2021)

Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol
por: Nichols, Gregory A., et al.
Publicado: (2018)

Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT
por: Selvaraj, Senthil, et al.
Publicado: (2022)

Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
por: Budoff, Matthew J, et al.
Publicado: (2020)

A Head‐to‐Head Comparison of a Free Fatty Acid Formulation of Omega‐3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE‐IT Study
por: Maki, Kevin C., et al.
Publicado: (2022)

Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007–2014
por: Fan, Wenjun, et al.
Publicado: (2020)

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk
por: Toth, Peter P., et al.
Publicado: (2018)

Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn
por: Miller, Michael, et al.
Publicado: (2023)

Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking
por: Miller, Michael, et al.
Publicado: (2022)

Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins
por: Leatherman, Sarah, et al.
Publicado: (2022)

The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function
por: Di Costanzo, Assunta, et al.
Publicado: (2023)

Icosapent ethyl for the treatment of severe hypertriglyceridemia
por: Fares, Hassan, et al.
Publicado: (2014)

Icosapent ethyl: scientific and legal controversies
por: Curfman, Gregory, et al.
Publicado: (2021)

The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl
por: Derington, Catherine G., et al.
Publicado: (2022)

Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007–2014
por: Fan, Wenjun, et al.
Publicado: (2020)

Prevalence of United States adults with triglycerides ≥ 135 mg/dL: NHANES 2007–2014
por: Fan, Wenjun, et al.
Publicado: (2019)

Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?
por: Scherer, Daniel J, et al.
Publicado: (2015)

Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high‐risk statin‐treated patients: A large administrative retrospective analysis
por: Toth, Peter P., et al.
Publicado: (2019)

Clinical results and mechanism of action of icosapent ethyl
por: Borghi, Claudio, et al.
Publicado: (2023)

Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study
por: Budoff, Matthew, et al.
Publicado: (2018)

Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis
por: Toth, Peter P., et al.
Publicado: (2019)

Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap
por: Parhofer, Klaus G, et al.
Publicado: (2020)

Icosapent Ethyl (Vascepa®) for the Treatment of Acute, Severe Pancreatitis
por: Berger, Amnon A, et al.
Publicado: (2020)

A randomized trial of icosapent ethyl in ambulatory patients with COVID-19
por: Kosmopoulos, Andrew, et al.
Publicado: (2021)

Effect of Concomitant Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on the Pharmacokinetics of Atorvastatin
por: Braeckman, Rene A., et al.
Publicado: (2014)

Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study
por: Ambrosy, Andrew P., et al.
Publicado: (2021)

Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China
por: Wang, Zhen, et al.
Publicado: (2023)

Potential Benefits of Icosapent Ethyl on the Lipid Profile: Case Studies
por: Hilleman, Daniel E., et al.
Publicado: (2014)

Beyond cardiovascular medicine: potential future uses of icosapent ethyl
por: Bhatt, Deepak L, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_18a3812t8vlbljtin5k3m8veld